Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)
April 02, 2024 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics announces acceptance of MAA by the EMA for obe-cel for patients with B-ALL
Autolus Therapeutics Announces Changes to its Board of Directors
April 01, 2024 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics Announces Changes to its Board of Directors
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
March 14, 2024 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
February 08, 2024 05:45 ET
|
Autolus Therapeutics plc; BioNTech SE
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)
January 22, 2024 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics announces acceptance of BLA for obe-cel as a potential treatment for relapsed/refractory adult ALL
Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of Directors
January 10, 2024 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of Directors
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023
December 09, 2023 20:30 ET
|
Autolus Therapeutics plc
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023
Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL)
November 27, 2023 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel)
Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023
November 15, 2023 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023
Autolus Therapeutics announces participation in upcoming conferences
November 06, 2023 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics announces participation in upcoming conferences